Report GN
Report GN
Report GN
DEPARTMENT OF BIOCHEMISTRY
CAMP FASTING SUGAR AND PP
Comment:
As per American Diabetes Guidelines, 2023
Page 1 of 3
SIN No:BI17825242
THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED-VIKAS MARG NEW DELHI
Patient Name : Mr.PAWAN MADHESIYA Collected : 13/Jan/2024 11:33AM
Age/Gender : 37 Y 3 M 16 D /M Received : 13/Jan/2024 03:04PM
UHID/MR No : APJ1.0017987728 Reported : 13/Jan/2024 03:34PM
Visit ID : DTRAOPV842 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC AMATRA -SECTOR 10
IP/OP NO : Patient location : ,Greater Noida
DEPARTMENT OF BIOCHEMISTRY
CAMP HBA1C
Comment:
Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:
REFERENCE GROUP HBA1C %
NON DIABETIC <5.7
PREDIABETES 5.7 – 6.4
DIABETES ≥ 6.5
DIABETICS
EXCELLENT CONTROL 6–7
FAIR TO GOOD CONTROL 7–8
UNSATISFACTORY CONTROL 8 – 10
POOR CONTROL >10
Note: Dietary preparation or fasting is not required.
1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic
Control by American Diabetes Association guidelines 2023.
2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation
is advised in interpretation of low Values.
4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age.
HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
A: HbF >25%
B: Homozygous Hemoglobinopathy.
(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)
Page 2 of 3
SIN No:BI17825241
THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED-VIKAS MARG NEW DELHI
Patient Name : Mr.PAWAN MADHESIYA Collected : 13/Jan/2024 11:33AM
Age/Gender : 37 Y 3 M 16 D /M Received : 13/Jan/2024 03:45PM
UHID/MR No : APJ1.0017987728 Reported : 13/Jan/2024 04:34PM
Visit ID : DTRAOPV842 Status : Final Report
Ref Doctor : Dr.SELF Client Name : PCC AMATRA -SECTOR 10
IP/OP NO : Patient location : ,Greater Noida
DEPARTMENT OF BIOCHEMISTRY
Comment:
ALT elevations are noted in liver parenchymal diseases, leading to injury / destruction of hepatocytes.
ALT levels are seen to be elevated even before the signs and symptoms of the liver injury appear.
The ALT levels remain high longer in blood as compared to AST levels. And though both the enzymes increase in liver injury, the rise in ALT is more compared to
AST, thus also altering the ALT:AST ratio.
Page 3 of 3
SIN No:BI17825243
THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED-VIKAS MARG NEW DELHI